Fujifilm Medical to add IVD to portfolio

LabPulse.com staff writers
Aug 16, 2020
2020 08 17 23 11 0044 Fujifilm Rsna 2019 400

Fujifilm Medical Systems USA has announced that as of October 1, it will incorporate IVD into its portfolio by integrating Fujifilm Wako Diagnostics USA into the firm.

Fujifilm Wako Diagnostics has developed biomarkers that assess the risk of hepatocellular carcinoma in patients with chronic liver disease, as well as IVD reagents for disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes, according to Fujifilm Medical Systems.

Latest in Hepatocellular Carcinoma
Liver Cancer Social
Gene mutations linked to drug-resistant liver cancer
June 26, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Liver Cancer
Bionano Genomics announces study of optical genome mapping for hepatocellular carcinoma
October 4, 2022
2019 08 20 22 16 4501 Liver Anatomy 400
Helio publishes study of HelioLiver cancer test
March 9, 2022
Related Stories
2021 06 08 21 44 7484 Cancer Cell Yellow 400
Liver Cancer
Biomarker assay may speed primary liver cancer detection
2020 05 07 22 15 9104 Thermo Fisher Scientific 400
Lupus
FDA clears Thermo Fisher's new blood test for lupus
2021 03 18 23 58 5869 Fujifilm Rsna 2019 400
Infectious
With Hitachi deal done, Fujifilm sets sights on healthcare growth
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Hepatocellular Carcinoma
Gene mutations linked to drug-resistant liver cancer
By Elissa Wolfson
Certain gene mutations could help physicians predict which hepatocellular carcinoma patients are most likely to develop drug resistance to lenvatinib.
June 26, 2023
Liver Cancer Social
Delfi Diagnostics to present proof-of-concept data for liver cancer detection platform
By LabPulse.com staff writers
Delfi Diagnostics will present data on the efficacy of their liver cancer detection platform at the American Association for the Study of Liver Disease annual meeting.
October 28, 2022
Liver Digital Tablet
Bionano Genomics announces study of optical genome mapping for hepatocellular carcinoma
By LabPulse.com staff writers
The study combined optical genome mapping with whole genome sequencing to maximize the detection of pathogenic variants.
October 4, 2022
Liver Cancer
Helio publishes study of HelioLiver cancer test
By LabPulse.com staff writers
In a prospective phase II study, HelioLiver demonstrated high specificity (91%) and high sensitivity (76%) in detecting early-stage (stage I and II) HCC. In addition, it significantly outperformed other clinically available detection tools such as serum alpha-fetoprotein (AFP) (57%), GALAD (gender, age, Lens culinaris agglutinin-reactive AFP, and des-gamma-carboxy prothrombin [DCP]) scores (65%), and ultrasound (47%) (Hepatology Communications, March 3, 2022).
March 9, 2022
2019 08 20 22 16 4501 Liver Anatomy 400
Liver cancer diagnostic test offers promise of early detection
By LabPulse.com staff writers
The platform is called EV Click Chips, and the hope is that it will enable more effective purification of extracellular vesicles in blood from people with hepatocellular carcinoma. Researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have received a $2.97 million grant from the U.S. National Cancer Institute (NCI) to develop the technology further.
August 4, 2020
2020 01 22 00 12 9591 Liver Cancer 400
Google reports pathology AI helps predict survival in cancer patients
By Emily Hayes
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
2020 06 16 21 12 7935 Artificial Intelligence Ai Hand 400
Blood test identifies patients at risk for liver cancer
By LabPulse.com staff writers
The test analyzes patients' previous viral exposure to accurately predict whether they might develop hepatocellular carcinoma (HCC). It was created by researchers from the U.S. National Institutes of Health and several academic centers to help improve liver cancer screening and early detection.
June 11, 2020
2019 08 20 22 16 4501 Liver Anatomy 400
Study calls for hepatitis D screening in at-risk patients
By LabPulse.com staff writers
A review of the literature suggests that those who have hepatitis D along with hepatitis B have up to three times the risk for developing hepatocellular carcinoma than if they had hepatitis B alone, reported researchers at the University of Geneva and Geneva University Hospitals, in an article in press. This assessment was based on an analysis of data from 93 studies including a total of more than 100,000 patients.
May 19, 2020
2020 05 19 23 52 8693 2020 05 20 Hepatitis D 400
Page 1 of 1